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Abstract 
Purpose 
The aim of this study is to assess the quality of reporting randomized 
controlled studies and investigated the efficacy and safety of new anticoagulants in 
acute venous thromboembolism or pulmonary embolism using a standard tool based 
on Consolidated Reporting Standards Tests (Consolidated Standards of Reporting 
Trials – CONSORT statement). 
Methods 
We searched Pubmed and the Cochrane Library until July 2015 for RCTs 
involving new anticoagulants in acute venous thromboembolism or pulmonary 
embolism. We used the Consolidated Standards of Reporting Trials (CONSORT) 
checklist for parallel RCTs revised in 2010 to assess the completeness of reporting of 
RCTs. 
Results 
Our search strategy identified 1197 studies, of which 6 met the inclusion 
criteria. From the six (6) RCTs, which were included in the analysis no-one 
mentioned the implementation of randomization in the title. All of them introduced 
random methods. Five studies were double-blinded and in those reported an 
estimation of sample size (83.34%). Five of them reported the statistical methods 
which used to compare groups for primary and secondary outcomes and methods for 
additional analyses (83.34%). All of them, reported, losses and exclusions after 
randomization. Only one study reported why the trial was stopped (16.67%). Three 
studies reported generalisability of the trial findings (50%) and two studies reported 
limitations or sources of potential bias of the trial (33.34%). 
Conclusion 
A well-designed RCT should use randomization and blinding. 
Endorsement of the CONSORT statement may optimize the reporting quality 
and enhance the validity of research. 
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Introduction 
Venous thromboembolism, manifested as deep vein thrombosis or pulmonary 
embolism, is a common medical condition and is the third leading cause of 
cardiovascular mortality. [1-7]
 
The mainstay of treatment has been initial use of 
parenteral anticoagulants followed by longer term use of oral vitamin K 
antagonists.[8] While the vitamin K antagonists are effective at preventing 
propagation and recurrence, they are also associated with an increased risk of 
bleeding and the need for laboratory monitoring.[9] In addition, they have potential 
for multiple drug-drug interactions, which are often clinically important because of 
their narrow therapeutic index. In the past decade two classes of novel oral 
anticoagulants have been developed: direct thrombin inhibitors (dabigatran) and 
factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban). Factor Xa inhibitors 
prevent cleavage of prothrombin to thrombin, whereas the direct thrombin inhibitors 
prevent thrombin from cleaving fibrinogen.[10]
 
Recent studies have evaluated the 
efficacy and safety of direct oral anticoagulants (with and without initial parenteral 
anticoagulant therapy) for the treatment of acute venous thromboembolism. 
Clinicians have many potential treatment options regarding management of acute 
venous thromboembolism and little guidance exists about which drug is most 
effective yet safe. Although individual studies have shown promising results, several 
therapies have been assessed in only a single trial, and direct comparisons are rarely 
available. 
Randomized controlled trials (RCTs) are considered the best tool for 
establishing effectiveness due to minimization of bias in evaluating new treatment 
strategies [11,12,13]. RCTs represent a key research activity with the potential to 
improve the quality of health care and control costs through careful comparison of 
alternative treatments [14,15]. However, the recent flood of available information in 
biomedical journals during the last years has raised problems in a variety of areas, 
such as publication or selection bias and retraction of invalid literature [11,16,17]. 
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An international group of scientists and editors developed and published in 
1996, a common checklist for items to include in reports of RCTs, known as the 
Consolidated Standards of Reporting Trials (CONSORT) statement [13,18]. It was 
initially published in 1996 [19], then revised twice subsequently in 2001 and 
2010.[20,21] The CONSORT provides structured guidance to help researchers 
prepare reports of trial findings, facilitate complete and transparent reporting, and aid 
in critical appraisal and interpretation. The most current version of the statement 
includes a 25-item checklist and a flow diagram. The checklist provides standardized 
approaches to report the trial design, analysis, and interpretation, and the diagram 
gives instructions to display the progress of all participants throughout the trial. 
The aim of this study is to assess the quality of reporting randomized 
controlled studies and investigated the efficacy and safety of new anticoagulants in 
acute venous thromboembolism or pulmonary embolism using a standard tool based 
on Consolidated Reporting Standards Tests (Consolidated Standards of Reporting 
Trials – CONSORT statement). 
Methods 
Data sources and searches 
A systematic search of the literature was conducted on Pubmed and the 
Cochrane Library. Each database was searched from its inception date to July 2015. 
References of included studies and narrative reviews were considered for additional 
potential studies. The retrieved articles were examined to eliminate potential 
duplicates or overlapping data. There were no language restrictions. The search string 
was: #1. (rivaroxaban) OR (apixaban) OR (edoxaban) #2. (dabigatran), #3. #2 OR #1 
[(rivaroxaban) OR (apixaban) OR (edoxaban) OR(dabigatran)], #4. deep venous 
thrombosism OR deep vein thrombosism OR thrombophlebitis OR pulmonary 
embolism, #5. #3 AND #4 [(rivaroxaban) OR (apixaban) OR (edoxaban) OR 
(dabigatran) AND deep venous thrombosism OR deep vein thrombosism OR 
thrombophlebitis OR pulmonary embolism]. 
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Study selection  
Potentially relevant articles were reviewed in full to ensure that they satisfied 5 
criteria: (1) the study prospectively enrolled patients who had objectively confirmed 
symptomatic acute venous thromboembolism (lower extremity deep vein thrombosis, 
pulmonary embolism, or both) and who had qualifying recurrent venous 
thromboembolism events that were symptomatic and objectively confirmed, (2) the 
intervention was treatment with a novel oral anticoagulants with or without initial 
treatment with heparin, (3) the comparison group was treatment with vitamin K 
antagonists always with initial treatment with heparin, (4) 1 or more of the primary or 
secondary outcomes were reported and (5) and it was a randomized controlled trial. 
Studies were excluded if (1) patients were randomized to placebo or observation, (2) 
patients were randomized to ximelagatran or idraparinux, (3) only patients with 
cancer-associated thrombosis were included and (4) study design was phase I or II. 
Data extraction and quality assessment 
We used the CONSORT statement for parallel RCTs revised in 2010 to assess 
the completeness of reporting of RCTs. The revised CONSORT checklist includes a 
25-item-questionaire. The methodological items include the use of the term 
“randomized trial” in the title, location of data collection, predefined primary 
outcome, sample size estimation, method of randomization sequence generation, 
allocation concealment and implementation, who was blind and how blinding was 
achieved, publication of a participant flow diagram, period of recruitment, period of 
follow-up, as well as the attrition due to loss to follow-up, and intention-to-treat 
analysis. [25] All items were investigated in terms of whether they were reported, not 
whether they were actually carried out during the trial. The items that reported in the 
study were assessed as ‘yes’. Otherwise, the item was rated as ‘no’. For an item that 
contained multiple subitems, the reporting of the item was considered to be complete 
when at least one subitem was completely reported. 
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Results 
Our search identified 1197 studies of interest, after removal of duplicates. Most 
studies were eliminated during screening as the indication for anticoagulation was not 
acute venous thromboembolism. After we reviewed 89 full text articles, six (6) 
studies with over 13.500 patients were suitable for data extraction and pooled 
analysis (figure 1). The trials evaluated two factor Xa inhibitors (rivaroxaban (two 
randomised controlled trials, n=4150), apixaban (one trial, n=2691) and edoxaban 
(one trial, n=4118)) and one direct thrombin inhibitors (dabigatran (two trials, 
n=2553)).[23,24,25,26,27,28] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Flow Diagram of Study Selection 
 
 
1197 Total records reviewed 
89 Articles were assessed for 
eligibility 
6 Records met all inclusion criteria 
and were included in the analyses 
1069 Excluded as irrelevant               
(not dealing with VTE or PE) 
83 Excluded 
11 Narrative or systematic reviews  
9 Subgroup analyses  
5 Cancer-associated thrombosis only  
4 Phase 1 or 2 studies  
3 Ximelagatran or Idraparinux 
22 Compared the UFH–vitamin K antagonist combination 
with the LMWH–vitamin K antagonist combination 
12 Compared the UFH–vitamin K antagonist combination 
with LMWH alone 
3 Compared the LMWH–vitamin K antagonist combination 
with LMWH alone 
2 Compared the fondaparinux–vitamin K antagonist 
combination with the LMWH–vitamin K antagonist 
combination or with the UFH–vitamin K antagonist 
12 Other (Not RCT) 
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 Rivaroxaban 
Two phase III studies were performed by the EINSTEIN investigators in a pair 
of open label non-inferiority studies. The EINSTEIN-DVT study enrolled 3449 
patients with acute deep vein thrombosis and excluded patients with symptomatic 
pulmonary embolism.[24] The EINSTEIN-PE study recruited 4832 patients with 
acute symptomatic pulmonary embolism with or without symptomatic deep vein 
thrombosis. [23] The EINSTEIN investigators chose to load rivaroxaban at 15 mg 
twice a day for three weeks followed 20 mg once a day with standard therapy with 
enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months. 
The rivaroxaban patients typically received one to two doses of low molecular weight 
heparin before starting rivaroxaban, whereas the patients randomised to vitamin K 
antagonists received low molecular weight heparin concurrently for five days or 
more, until the target international normalised ratio (INR) was achieved. 
 Apixaban 
A randomized, double-blind study compared apixaban (at a dose of 10 mg 
twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional 
therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute 
venous thromboembolism.[25] 
 Dabigatran 
The pivotal published study on dabigatran enrolled patients with acute venous 
thromboembolism who were initially given parenteral anticoagulation therapy for a 
median of 9 days.[27] This was a phase III non-inferiority, double blind, double 
dummy trial, which included sham monitoring of international normalised ratio (INR) 
and sham titration of vitamin K antagonists in the experimental group. Another 
randomized, double-blind, double-dummy trial of 2589 patients with acute VTE 
treated with low-molecular-weight or unfractionated heparin for 5 to 11 days, was 
designed to compare dabigatran 150 mg twice daily with warfarin, adjusted to 
maintain an international normalized ratio (INR) of 2.0 to 3.0 during 6 months, after 
initial parenteral anticoagulation.[28]  
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 Edoxaban 
We found one published studies that looked at edoxaban. In this randomized, 
double-blind trial, investigators compared heparin (enoxaparin or unfractionated 
heparin) followed by edoxaban with heparin followed by warfarin with respect to 
efficacy and safety in patients with deep-vein thrombosis, pulmonary embolism, or 
both. Edoxaban (or placebo) was started after discontinuation of initial heparin. 
Edoxaban was administered at a dose of 60 mg orally once daily, taken with or 
without food, or at a dose of 30 mg once daily in patients with a creatinine clearance 
of 30 to 50 ml per minute or a body weight of 60 kg or less or in patients who were 
receiving concomitant treatment with potent P-glycoprotein inhibitors. Warfarin (or 
placebo) was started concurrently with the study regimen of heparin, with adjustment 
of the dose to maintain the international normalized ratio (INR) between 2.0 and 3.0. 
Treatment with edoxaban or warfarin was to be continued for at least 3 months in all 
patients and for a maximum of 12 months. [26] 
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Section/Topic Item 
No 
Checklist item Study 1 Study 2 Study 3 Study 4 Study 5 Study 6 
Title and abstract      
 1a Identification as a randomised trial in the title No No No No No No 
1b Structured summary of trial design, methods, results, and conclusions  Yes Yes Yes Yes Yes Yes 
Introduction      
Background and 
objectives 
2a Scientific background and explanation of rationale Yes Yes Yes Yes Yes Yes 
2b Specific objectives or hypotheses No Yes No Yes Yes Yes 
Methods      
Trial design 3a Description of trial design including allocation ratio Yes Yes Yes Yes Yes Yes 
3b Important changes to methods after trial commencement, with reasons No No No No No Yes 
Participants 4a Eligibility criteria for participants Yes Yes Yes Yes Yes No 
4b Settings and locations where the data were collected Yes No Yes Yes Yes Yes 
Interventions 5 The interventions for each group with sufficient details to allow replication, including 
how and when they were actually administered 
Yes Yes Yes Yes Yes Yes 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, 
including how and when they were assessed 
Yes Yes Yes Yes Yes Yes 
6b Any changes to trial outcomes after the trial commenced, with reasons Yes No Yes No No Yes 
Sample size 7a How sample size was determined No Yes Yes Yes Yes Yes 
7b When applicable, explanation of any interim analyses and stopping guidelines Yes Yes No Yes No No 
Randomisation:         
 Sequence 
generation 
8a Method used to generate the random allocation sequence Yes Yes Yes Yes Yes Yes 
8b Type of randomisation; details of any restriction (such as blocking and block size) Yes Yes Yes Yes Yes Yes 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence, describing any 
steps taken to conceal the sequence until interventions were assigned 
No No Yes No Yes No 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who 
assigned participants to interventions 
Yes No Yes Yes No No 
Blinding 11a If done, who was blinded after assignment to interventions and how No Yes Yes Yes Yes Yes 
11b If relevant, description of the similarity of interventions Yes No No Yes Yes Yes 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes Yes No Yes Yes Yes Yes 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses Yes Yes Yes Yes No Yes 
Results      
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received 
intended treatment, and were analysed for the primary outcome 
Yes Yes Yes Yes Yes Yes 
13b For each group, losses and exclusions after randomisation, together with reasons Yes Yes Yes Yes Yes Yes 
Recruitment 14a Dates defining the periods of recruitment and follow-up Yes Yes Yes Yes Yes Yes 
14b Why the trial ended or was stopped No No No No No No 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Yes Yes Yes Yes Yes Yes 
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Numbers analysed 16 For each group, number of participants  included in each analysis and whether the 
analysis was by original assigned groups 
Yes Yes Yes Yes Yes Yes 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated 
effect size and its precision  
Yes Yes Yes Yes Yes Yes 
17b For binary outcomes, presentation of both absolute and relative effect sizes is 
recommended 
No No No No No No 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from exploratory 
Yes Yes Yes Yes No Yes 
Harms 19 All important harms or unintended effects in each group  No Yes Yes Yes Yes Yes 
Discussion      
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, 
multiplicity of analyses 
Yes Yes Yes No Yes No 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings No Yes Yes Yes No No 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering 
other relevant evidence 
Yes Yes Yes Yes Yes Yes 
Other information 
      
Registration 23 Registration number and name of trial registry Yes Yes Yes Yes Yes Yes 
Protocol 24 Where the full trial protocol can be accessed, if available Yes Yes Yes Yes No No 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders Yes Yes Yes Yes Yes Yes 
Table 2: Proportion of reporting of 25 data items in a total of 6 randomized clinical trials in acute venous thromboembolism or pulmonary embolism. (Study 1: Oral Rivaroxaban for the Treatment of 
Symptomatic Pulmonary Embolism, Study 2: Oral Rivaroxaban for Symptomatic Venous Thromboembolism, Study 3: Oral Apixaban for the Treatment of Acute Venous Thromboembolism, Study 4: Edoxaban 
versus warfarin for the treatment of symptomatic venous thromboembolism, Study 5: Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism, Study 6: Treatment of acute venous 
thromboembolism with dabigatran or warfarin and pooled analysis) 
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Section/Topic Item 
No 
Checklist item Number of 
reported 
RCTs 
[n (%)] 
Title and abstract 
 1a Identification as a randomised trial in the title 0 
1b Structured summary of trial design, methods, results, and conclusions  6/6 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 6/6 
2b Specific objectives or hypotheses 4/6 (66.67%) 
Methods 
Trial design 3a Description of trial design including allocation ratio 6/6 
3b Important changes to methods after trial commencement, with reasons 1/6 (16.67%) 
Participants 4a Eligibility criteria for participants 5/6 (83.34%) 
4b Settings and locations where the data were collected 5/6 (83.34%) 
Interventions 5 The interventions for each group with sufficient details to allow replication, including 
how and when they were actually administered 
6/6 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, 
including how and when they were assessed 
6/6 
6b Any changes to trial outcomes after the trial commenced, with reasons 3/6 (50%) 
Sample size 7a How sample size was determined 6/6 
7b When applicable, explanation of any interim analyses and stopping guidelines 3/6 (50%) 
Randomisation:    
 Sequence generation 8a Method used to generate the random allocation sequence 6/6 
8b Type of randomisation; details of any restriction (such as blocking and block size) 6/6 
 Allocation concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence, describing any 
steps taken to conceal the sequence until interventions were assigned 
3/6 (50%) 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who 
assigned participants to interventions 
3/6 (50%) 
Blinding 11a If done, who was blinded after assignment to interventions and how 5/6 (83.34%) 
11b If relevant, description of the similarity of interventions 4/6 (66.67%) 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 5/6 (83.34%) 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 5/6 (83.34%) 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received 
intended treatment, and were analysed for the primary outcome 
6/6 
13b For each group, losses and exclusions after randomisation, together with reasons 6/6 
Recruitment 14a Dates defining the periods of recruitment and follow-up 6/6 
14b Why the trial ended or was stopped 0 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 6/6 
Numbers analysed 16 For each group, number of participants  included in each analysis and whether the 
analysis was by original assigned groups 
6/6 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated 
effect size and its precision  
6/6 
17b For binary outcomes, presentation of both absolute and relative effect sizes is 
recommended 
0 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from exploratory 
5/6 (83.34%) 
Harms 19 All important harms or unintended effects in each group  5/6 (83.34%) 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, 
multiplicity of analyses 
4/6 (66.67%) 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 3/6 (50%) 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering 
other relevant evidence 
6/6 
Other information 
 
Registration 23 Registration number and name of trial registry 6/6 
Protocol 24 Where the full trial protocol can be accessed, if available 4/6 (66.67%) 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 6/6 
Table 3:Reporting quality of 6 RCTs based on CONSORT 2010 
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CONSORT 2010 adherence 
From the six (6) RCTs, which were included in the analysis no-one mentioned the 
implementation of randomization in the title. However, all of them introduced random 
methods. Of them, four used a voice-response system with stratification, one used a 
computer generated randomization scheme with variable block sizes and one used an 
interactive Web-based system. Five studies were double-blinded and in those reported 
an estimation of sample size. Only one study reported important changes to methods 
after trial commencement, with reasons. In which were reported that the protocol stated 
as hierarchically equal safety outcomes major bleeding, major or clinically relevant 
nonmajor bleeding, and any bleeding but was not planned for independent central 
adjudication of acute coronary syndromes, so this decision was revised by the steering 
committee and performed at the end of the trial, after database locked. 
Five of them reported the statistical methods which used to compare groups for 
primary and secondary outcomes and methods for additional analyses. All of them 
reported, losses and exclusions after randomization, together with reasons and included 
a table showing the baseline demographic and clinical characteristics for each group. 
Three studies reported generalisability of the trial findings and two studies reported 
limitations or sources of potential bias of the trial. No one study reported why the trial 
was stopped. All of the included studies reported sources of funding and the registration 
number. Four studies mentioned, where the full protocol was available. Only one trial 
did not report the eligibility criteria for participants, however report that they are 
described in another study, and gives us the referral. 
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CONCLUSION 
We prepared this study to assess the quality of reporting randomized controlled 
studies and investigated the efficacy and safety of new anticoagulants in acute venous 
thromboembolism or pulmonary embolism. In our search we decided to exclude the 
direct thrombin inhibitor ximelagatran which was withdrawn from the market in 2006 
because of concerns over hepatotoxicity. We also exclude idraparinux because is oldest 
than the other four anticoagulants that we include in our alanysis. 
 We searched on Pubmed and the Cochrane Library up to July 2015. Our search 
strategy identified 1197 studies, of which 6 met the inclusion criteria. We evaluated the 
quality of reporting using the CONSORT Statement checklists. 
A well-designed RCT should use randomization and blinding. Widely acceptable 
methods should be used to generate a random allocation sequence and an allocation 
concealment mechanism should be used. All of the studies which were included in the 
analysis introduced random methods but only three of them reported the mechanism 
used to implement the random allocation sequence. Five studies were double-blinded 
and reported the methods of statistical analysis. 
In general, the studies included in the analysis meet most of the requirements of a 
good randomized trial. However, the design of RCTs, the methods of statistical analysis, 
and other parts of the study should be improved and the reporting of RCTs should 
follow the CONSORT 2010. 
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